Flerie advances TOL2 into pivotal trials for myasthenia gravis treatment

Flerie has completed the integration of Toleranzia AB into its business portfolio. The company's flagship drug candidate, TOL2, is now moving into a crucial development stage. Designed to treat myasthenia gravis, an autoimmune disease, the project has drawn attention from market analysts.

TOL2 is currently undergoing Phase I/IIa clinical trials across several European markets, including Germany. While the exact number of trial centres remains unspecified, the study is progressing as planned. Analysts consider the drug a promising candidate that could significantly impact treatment options for patients.

Flerie's operational restructuring also involved transferring Toleranzia's business activities to Bonsai Biotherapeutics AB. In March 2026, shareholders approved a bonus share issue to support further development. To fund this growth, no dividend was paid out for the previous fiscal year. The record date for bonus share allocations was set for May 18, 2026. On this date, the technical processing of share distributions took place in shareholders' accounts.

TOL2's advancement into a critical development phase marks a key step for Flerie and its investors. The company's decision to reinvest funds into product development reflects its focus on bringing the drug to market. Shareholders will now await further updates on trial progress and regulatory milestones.